Top Markets
Coin of the day
Alpine Immune Sciences, Inc. Alpine Immune Sciences, Inc.

Alpine Immune Sciences, Inc.

ALPN
株式のランク #6581
Alpine Immune Sciences, Inc. is a clinical-stage biopharmaceutical company... Alpine Immune Sciences, Inc. is a clinical-stage biopharmaceutical company focused on discovering and advancing protein-based immunotherapies. Their therapeutic endeavors address a range of conditions, including various cancers, autoimmune and inflammatory disorders, among others. The company's pipeline features ALPN-101, an ICOS/CD28 antagonist program being developed for autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor aimed at treating cancer; and ALPN-303, a dual B cell cytokine antagonist for B cell-mediated inflammatory and autoimmune conditions. Alpine Immune Sciences has established strategic collaborations, including an agreement with AbbVie Ireland Unlimited Company for the development of ALPN-101, and a partnership with Adaptimmune Therapeutics plc to create next-generation SPEAR T cell products. The company was founded in 2007 and operates from its headquarters in Seattle, Washington.
株価
$64.97
最終同期: 2024-05-20
時価総額
$1.97B
変化(1日)
0.00%
変化(1年)
0.00%
US
取引 Alpine Immune Sciences, Inc. (ALPN)

カテゴリー

Alpine Immune Sciences, Inc.(ALPN)の発行済株式数
March 2024 時点の発行済株式数 64.03M
Alpine Immune Sciences, Inc. の最新の財務報告および株価によると、現在の発行済株式数は 64.03M です。December 2022 の終わりには、同社は 33.44M 株の発行済株式 を有していました。発行済株式数は、通常、株式分割や自社株買いによって影響を受けます。
Alpine Immune Sciences, Inc.(ALPN)の発行済株式数の履歴(2012 ~ 2026)
各年末時点の発行済株式数
発行済株式数 変化
2026 (TTM) 64.03M 28.07%
2023 50.00M 49.54%
2022 33.44M 31.24%
2021 25.48M 22.33%
2020 20.83M 13.44%
2019 18.36M 32.56%
2018 13.85M 113.67%
2017 6.48M 67.36%
2016 3.87M 65.32%
2015 2.34M 2.70%
2014 2.28M 0.00%
2013 2.28M 0.00%
2012 2.28M 0.00%
類似企業や競合他社の発行済株式数
企業 発行済株式数
253.90M 296.51%
US
62.19M -2.89%
NL
478.91M 647.91%
AU
396.00M 518.43%
US
- -
CH